Medarex Reports Interim Data From Ongoing Ipilimumab Combination Phase 1 Studies In Prostate Cancer At American Association For Cancer Research

Medarex, Inc. (Nasdaq: MEDX) announced interim results from two ongoing Phase 1 trials in hormone refractory prostate cancer (HRPC) demonstrating dose-dependent T-cell activation and clinical activity of ipilimumab, an investigational anti-CTLA-4 antibody.

More: continued here

Filed under: Endocrinology on April 17th, 2008